Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 3/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577358 | 0.86 | AGXT (0.57) | AGXTPRMT6L3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL4576693 | 0.80 | CHKA (0.47) | L3MBTL3L3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL10244433 | 0.78 | PRMT6 (0.61) | AGXTPRMT6L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL4806907 | 0.78 | AGXT (0.58) | AGXTPRMT6L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL4576250 | 0.77 | AGXT (0.54) | AGXTPRMT6L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL27526754 | 0.76 | PRMT6 (0.55) | AGXTPRMT6L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL2554494 | 0.76 | ALDH1A1 (0.55) | AGXTPRMT6L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL27526752 | 0.76 | PRMT6 (0.55) | AGXTPRMT6L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL4808902 | 0.75 | L3MBTL3 (0.72) | AGXTPRMT6L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL10752458 | 0.75 | PRMT6 (0.54) | AGXTPRMT6L3MBTL3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1931994-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | MISSBACH MARTIN | 2007-06-14 | — | — | US | disclosed |
| WO-2007038397-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | ZIMMERMANN JOHANN | 2006-12-14 | — | — | US | disclosed |
| EP-1423121-B1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-7112589-B2 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | CTSK, CTSB, CTSZ | AGXT 2994/4885PRMT6 3202/4885L3MBTL3 2555/4885 |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | AGXT 1279/4885PRMT6 2177/4885L3MBTL3 4536/4885 |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | CTSK, CTSB, CTSZ | AGXT 4398/4885PRMT6 4576/4885L3MBTL3 2681/4885 |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | BST2, BSG, CD44 | AGXT 4502/4885PRMT6 3715/4885L3MBTL3 2131/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | AGXT 1197/4885PRMT6 2046/4885L3MBTL3 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.